Polish drug developer Selvita has out-licenced its first lead compound to Berlin-Chemie Menarini, a company of the Menarini Group. Ongoing clinical trails with SEL 24 will be conducted the company listed on Warsaw Stock Exchange and taken over later this year by Menarini.
https://european-biotechnology.com/wp-content/uploads/2024/04/Selvita_CEO_Pawel_Przewiezlikowski.png478700Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-29 07:28:202017-03-29 07:28:20Selvita to cash in €90m in Menarini deal
The EU’s opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation for political reasons.
Good news for EMD Serono, the US arm of German Merck: It’s PD-L1 blocker avelumab is the first drug that received FDA approval to treat the rare skin cancer Merkel Cell Carcinoma (MCC).
Scientists at EPFL in Lausanne have developed a semi-automated technology that may be a game-changer by making the characterisation of the 2,000 DNA-binding proteins much faster, more accurate, and efficient.
With around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life sciences.
?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014.
https://european-biotechnology.com/wp-content/uploads/2024/04/julien-le-guyader.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-03-21 16:52:392024-04-02 14:36:05Dentons: All about taxes
Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Belgian clinical-stage immunotherapy developer Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011.
British inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-20 10:18:592017-03-20 10:18:59Pulmocide raises £25m in Series B round
Selvita to cash in €90m in Menarini deal
Latest NewsPolish drug developer Selvita has out-licenced its first lead compound to Berlin-Chemie Menarini, a company of the Menarini Group. Ongoing clinical trails with SEL 24 will be conducted the company listed on Warsaw Stock Exchange and taken over later this year by Menarini.
EU nations go on blocking GM crops
Latest NewsThe EU’s opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation for political reasons.
EMA backs three orphan drugs
Latest NewsThree of six new meds to be approved in Europe are orphan drugs and have been backed by the European Medicines Agency (EMA) this month.
FDA approves Merck’s avelumab in MCC
Latest NewsGood news for EMD Serono, the US arm of German Merck: It’s PD-L1 blocker avelumab is the first drug that received FDA approval to treat the rare skin cancer Merkel Cell Carcinoma (MCC).
Microfluidics: Mapping DNA-binders
BackgroundScientists at EPFL in Lausanne have developed a semi-automated technology that may be a game-changer by making the characterisation of the 2,000 DNA-binding proteins much faster, more accurate, and efficient.
BIO-Europe Spring: Southern growth ambitions
Latest NewsWith around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBD’s partnering event. Southern Europe demonstrated its growth ambitions in the life sciences.
Dentons: All about taxes
AppointmentsToxoplasmosis: novel target to prevent transmission
Latest NewsScottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Asit biotech: Expertise in vaccines
AppointmentsPulmocide raises £25m in Series B round
Latest NewsBritish inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.